AI Empowered Breakthroughs and Innovations in Drug Development
DOI:
https://doi.org/10.54097/qccmjw78Keywords:
Artificial intelligence, Drug discovery, Target identification, Molecular design, Clinical trialsAbstract
The development of novel drugs has long faced the severe challenge of the "Double Ten Law," with pharmaceutical R&D persistently encountering the "triple dilemma" of prolonged cycles, high costs, and low success rates, falling into the trap of "anti-Moore's Law." The rise of artificial intelligence (AI) technology offers a comprehensive solution to this predicament, achieving efficiency revolutions across all stages—from target discovery and molecular design to clinical trials. To outline the technological evolution of AI in drug discovery and design and analyze its role in driving innovative models for new drug discovery, this study conducts a systematic literature review and case analysis. It focuses on the core pain points of traditional drug development, elaborates on the application pathways and technological innovations of AI throughout the drug development process, presents practical achievements and potential enabled by AI based on real-world data, examines current challenges in data, technology, and talent, and outlines future prospects. The findings aim to provide insights for technological innovation and industrial upgrading in the field of drug development.
Downloads
References
[1] Li, X., Yuan, Q., Zhu, F., Wang, L., Zhang, Y., & Chen, H. (2025). Current status and future prospects of artificial intelligence application in clinical practice. China Clinical Research, 38(5), 657-662.
https://doi.org/10.13429/j.cnki.cjcr.2025.05.001
[2] Wu, M., Chen, X., Lin, L., Huang, J., & Zheng, Y. (2025). Application and prospects of artificial intelligence technology in drug design. China Prescription Drug, 23(24), 120-123.
[3] Zhang, J., Shao, X., & Fan, X. (2026). From predictive intelligence to generative intelligence: A new landscape of drug discovery and design led by artificial intelligence. Chinese Pharmaceutical Affairs, 40(1), 32-44.
https://doi.org/10.16153/j.1002-7777.2025-11-0011
[4] Xu, Y., & Pei, J. (2017). Application of deep learning in cheminformatics. Big Data, 3(2), 45-66.
[5] Heid, E., Greenman, K. P., Chung, Y., Li, S., Graff, D. E., Vermeire, F. H., Wu, H., Green, W. H., & McGill, C. J. (2023). Chemprop: A machine learning package for chemical property prediction. Journal of Chemical Information and Modeling, 64(1), 9-17. https://doi.org/10.1021/acs.jcim.3c01250
[6] Wieder, O., Kohlbacher, S., Kuenemann, M., Garon, A., Ducrot, P., Seidel, T., & Langer, T. (2020). A compact review of molecular property prediction with graph neural networks. Drug Discovery Today: Technologies, 37, 1-12. https://doi.org/10.1016/j.ddtec.2020.11.009
[7] Scalia, G., Grambow, C. A., Pernici, B., Li, Y. P., & Green, W. H. (2020). Evaluating scalable uncertainty estimation methods for deep learning-based molecular property prediction. Journal of Chemical Information and Modeling, 60(6), 2697-2717. https://doi.org/10.1021/acs.jcim.9b00975
[8] Wang, W., & Huang, X. (2025). Artificial intelligence-assisted drug design. China Journal of Bioengineering, 45(11), 1-9. https://doi.org/10.13523/j.cb.202505046
[9] Chen, Y., Wang, Z., Zeng, X., Huang, Y., & Li, Y. (2023). Molecular language models: RNNs or transformers? Briefings in Functional Genomics, 22(4), 392-400.
https://doi.org/10.1093/bfgp/elad012
[10] Liu, H., Zhu, B., Nie, S., Li, M., Zhou, J., Zhang, Y., Chen, W., & Wang, L. (2025). Advancing ADMET prediction through multiscale fragment-aware pretraining with Msformer-ADMET. Briefings in Bioinformatics, 26(5), bbaf506. https://doi.org/10.1093/bib/bbaf506
[11] Zhu, B., Li, Z., Jin, Z., Wang, X., Liu, H., Chen, G., & Zhang, Y. (2024). Knowledge-based in silico fragmentation and annotation of mass spectra for natural products with MassKG. Computational and Structural Biotechnology Journal, 23, 3327-3341. https://doi.org/10.1016/j.csbj.2024.08.022
[12] Zhou, G., Rusnak, D. V., Park, H. S., Yuan, Q., Wang, F., Zhang, L., & Wu, J. (2024). Artificial intelligence accelerated virtual screening platform for drug discovery. Nature Communications, 15, 7761. https://doi.org/10.1038/s41467-024-52033-7
[13] Ghozali, M. T. (2024). Predicting patient adherence in healthcare using artificial intelligence and machine learning techniques: A narrative review. In 2024 8th International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC) (pp. 1211-1215). IEEE.
https://doi.org/10.1109/I-SMAC61858.2024.10714872
[14] Crescenzo, R., Idoine, A., By, K., Viquez, A., & Chang, J. (2023). OP112 evaluation of a self-administered smart phone-based application as a wellness measure in a clinical trial of zanubrutinib. International Journal of Technology Assessment in Health Care, 39(S1), S31.
https://doi.org/10.1017/S026646232300115X
[15] Smalley, E. (2017). AI-powered drug discovery captures pharma interest. Nature Biotechnology, 35(7), 604-605. https://doi.org/10.1038/nbt.3914
[16] Zhiyuan Community. (2026). 1950s vs today: Productivity crisis in drug development and AI solutions [Report].
[17] Deloitte. (2025). Global drug R&D cost report 2025 [Report].
[18] Chen, B., Lü, L., Xu, X., Wang, Y., Zhang, M., & Liu, Z. (2024). Reflections on improving drug success rates with AIDD and CADD. Journal of China Pharmaceutical University, 55(3), 284-294.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Computing and Electronic Information Management
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
